Ticks, Mammal Vaccine Ingredients and Alpha-gal Allergy
Alpha-gal syndrome (AGS), the delayed, potentially fatal red meat allergy acquired through tick bites, has increased dramatically in the United States, and cases have also been reported in Sweden, Germany and Australia.1 As of 2013, more than 5,000 people in the Southwest U.S. have been diagnosed with the condition.2 In 2007, Scott Commins, MD, an […]
Trojan Horse of Measles—More Vaccines With the Mandate
Opinion | Bills to either remove or restrict vaccine exemptions have been filed across the U.S. in 2019. One of the most striking was New York’s A2371, which eliminated the religious exemption to vaccination in one day, with no public hearings. Soon after, New York state health officials eliminated the ability of doctors to grant medical […]
Fluzone Quadrivalent Influenza Vaccine Approved by FDA for Elderly
The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (BLA) for the Fluzone high-dose quadrivalent influenza vaccine for use by adults 65 years of age and older. Fluzone is manufactured by Sanofi Pasteur, Inc. of France.1 2 The Fluzone high-dose influenza vaccine was approved by the FDA in 2009 as […]
Flu Shot Fails to Protect Seniors and May Increase Miscarriages
Opinion | Flu season is creeping up on us again and there are widespread calls to get your annual flu shot, despite the fact that, year after year, this strategy turns out to have an abysmal rate of effectiveness across the board. One group that consistently turns out to draw the short end of the stick […]
The Pill Pitch
Prescription drugs help many people and even save lives. But use of prescription drugs as prescribed is also a leading cause of death in the U.S. Are some pharmaceutical companies skirting TV ad rules so that they don’t have to disclose side effects of some vaccines and other prescription medicine? Some critics say “yes.” And […]
Novartis Manipulated Data in FDA Biologics License Application
On Aug. 6, 2019, the U.S. Food and Drug Administration (FDA) issued a statement saying that Swiss pharmaceutical company Novartis AG submitted a biologics license application (BLA) for the spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi) with manipulated data and failed to inform regulators until June 28, 2019—more than a month after the […]